Biogen posts higher profit as new MS drug again tops forecasts
April 23, 2014 at 07:17 AM EDT
April 23 (Reuters) - Biogen Idec Inc on Wednesday reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended its run of eclipsing Wall Street sales forecasts.